Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M110,044Revenue (TTM) $M37,751Net Margin (%)12.8Altman Z-Score2.0
Enterprise Value $M117,112EPS (TTM) $1.8Operating Margin %15.9Piotroski F-Score5
P/E(ttm)23.2Beneish M-Score-2.3Pre-tax Margin (%)14.7Higher ROA y-yN
Price/Book1.710-y EBITDA Growth Rate %0.3Quick Ratio1.4Cash flow > EarningsN
Price/Sales2.95-y EBITDA Growth Rate %-2.8Current Ratio1.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %0.4ROA % (ttm)7.3Higher Current Ratio y-yN
Dividend Yield %4.0PEG--ROE % (ttm)12.7Less Shares Outstanding y-yY
Payout Ratio %87.0Shares Outstanding M2,611ROIC % (ttm)12.3Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYCharles Brandes 2016-03-31 Add0.78%$38.37 - $42.65
($40.17)
$ 42.145%Add 61.76%3,556,721
SNYDodge & Cox 2016-03-31 Add0.14%$38.37 - $42.65
($40.17)
$ 42.145%Add 7.24%53,530,129
SNYNWQ Managers 2016-03-31 Reduce-0.09%$38.37 - $42.65
($40.17)
$ 42.145%Reduce -6.34%1,946,427
SNYBill Nygren 2016-03-31 Reduce-0.05%$38.37 - $42.65
($40.17)
$ 42.145%Reduce -3.53%5,470,000
SNYBarrow, Hanley, Mewhinney & Strauss 2016-03-31 Reduce-0.03%$38.37 - $42.65
($40.17)
$ 42.145%Reduce -1.36%29,087,790
SNYJoel Greenblatt 2016-03-31 Buy 0.02%$38.37 - $42.65
($40.17)
$ 42.145%New holding34,720
SNYDavid Dreman 2016-03-31 Buy 0.01%$38.37 - $42.65
($40.17)
$ 42.145%New holding1,870
SNYKen Fisher 2016-03-31 Add0.01%$38.37 - $42.65
($40.17)
$ 42.145%Add 0.97%13,546,950
SNYHOTCHKIS & WILEY 2016-03-31 Add$38.37 - $42.65
($40.17)
$ 42.145%Add 0.23%10,164,994
SNYMario Gabelli 2016-03-31 Sold Out $38.37 - $42.65
($40.17)
$ 42.145%Sold Out0
SNYNWQ Managers 2015-12-31 Reduce-0.31%$41.51 - $51.49
($45.91)
$ 42.14-8%Reduce -16.94%2,078,119
SNYHOTCHKIS & WILEY 2015-12-31 Add0.19%$41.51 - $51.49
($45.91)
$ 42.14-8%Add 12.24%10,141,383
SNYCharles Brandes 2015-12-31 Reduce-0.06%$41.51 - $51.49
($45.91)
$ 42.14-8%Reduce -3.98%2,198,827
SNYBarrow, Hanley, Mewhinney & Strauss 2015-12-31 Add0.02%$41.51 - $51.49
($45.91)
$ 42.14-8%Add 1.26%29,489,368
SNYKen Fisher 2015-12-31 Add0.01%$41.51 - $51.49
($45.98)
$ 42.14-8%Add 0.90%13,416,220
SNYDavid Dreman 2015-12-31 Sold Out -0.01%$41.51 - $51.49
($45.91)
$ 42.14-8%Sold Out0
SNYDodge & Cox 2015-12-31 Add$41.51 - $51.49
($45.91)
$ 42.14-8%Add 0.11%49,915,073
SNYHOTCHKIS & WILEY 2015-09-30 Reduce-0.29%$46.64 - $54.98
($50.92)
$ 42.14-17%Reduce -15.57%9,035,695
SNYCharles Brandes 2015-09-30 Reduce-0.17%$46.64 - $54.98
($50.92)
$ 42.14-17%Reduce -10.56%2,290,031
SNYNWQ Managers 2015-09-30 Reduce-0.09%$46.64 - $54.98
($50.92)
$ 42.14-17%Reduce -5.10%2,501,826
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-55.64view
Sanofi10% Owner 2015-01-26Buy647,448$95-55.64view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-54.77view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-36.99view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67449.41view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    Why Berkshire Hathaway Dumped Johnson & Johnson Jul 19 2016 
    Investing in Big Pharma: Pointers on Pfizer Jul 14 2016 
    Pfizer, Merck, Other Big Pharmas Likely to Acquire Marijuana-Based Drug Companies Jun 13 2016 
    Endonovo Therapeutics: Innovative Treatment, Catalyst Create Compelling Opportunity May 22 2016 
    Charles Brandes Trims Stake in South American Petroleum Company May 13 2016 
    Warren Buffett’s Top 5 Dividend Yielding Stocks Apr 26 2016 
    Manning & Napier Sells Chunks of Stakes in GE, Eli Lilly, Merck Mar 29 2016 
    Amgen: Should I Just Sit and Wait? Mar 18 2016 
    Sanofi's New Products Will Fuel Sales Mar 13 2016 
    Warren Buffett's Worst Performing Stocks Mar 03 2016 

    More From Other Websites
    Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen Jul 25 2016
    Mylan’s EpiPen price increases are Valeant-like in size, Shkreli-like in approach Jul 23 2016
    Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other Jul 22 2016
    Six Major Biotech Acquisitions You Could See in 2016 (Part 2) Jul 22 2016
    Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal Jul 21 2016
    How Analysts Think Investors Should Play Vertex Pharmaceuticals Jul 21 2016
    Investors Scour Big Pharma M&A Scene for Next Big Takeover Jul 21 2016
    VBIV: A Differentiated Immunology Company With Multiple Near Term Value Drivers Jul 20 2016
    EU mergers and takeovers (July 19) Jul 19 2016
    The Most Popular French Stocks Among Hedge Funds Jul 15 2016
    The UN's War On Medical Innovations Jul 14 2016
    Why Relypsa Stock Is Ripping Jul 12 2016
    Icagen, out from under Pfizer's umbrella, raises $1.5 million Jul 08 2016
    Drugmaker Boehringer offers EU concessions for Sanofi asset swap Jul 08 2016
    San Antonio cancer therapeutics company taps familiar expertise Jul 08 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)